Functional improvement of dystrophic muscle by myostatin blockade
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Mice and cattle with mutations in the myostatin (GDF8) gene show a marked increase in body weight and muscle mass, indicating that this new member of the TGF-beta superfamily is a negative regulator of skeletal muscle growth. Inhibition of the myostatin gene product is predicted to increase muscle mass and improve the disease phenotype in a variety of primary and secondary myopathies. We tested the ability of inhibition of myostatin in vivo to ameliorate the dystrophic phenotype in the mdx mouse model of Duchenne muscular dystrophy (DMD). Blockade of endogenous myostatin by using intraperitoneal injections of blocking antibodies for three months resulted in an increase in body weight, muscle mass, muscle size and absolute muscle strength in mdx mouse muscle along with a significant decrease in muscle degeneration and concentrations of serum creatine kinase. The functional improvement of dystrophic muscle by myostatin blockade provides a novel, pharmacological strategy for treatment of diseases associated with muscle wasting such as DMD, and circumvents the major problems associated with conventional gene therapy in these disorders.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The interest in myostatin was generated by recent studies where antibodies for myostatin were created and administered to adult rodents, which resulted in an increase in body mass, muscle mass, muscle size, and strength [11,12].”
From Effects of methoxyisoflavone, ecdysterone, and sulfo-polysaccharide supplementation on training adaptations in resistance-trained males (2006) · cites this paper as [12]
Citations
Cites
Textbook of Medical Physiology
(1966) · Annals of Internal Medicine · doi:10.7326/0003-4819-64-6-1363_2 · Cited by 9,749
Dystrophin: the protein product of the Duchenne muscular dystrophy locus
Hoffman, E. P., Brown, R. H., & Kunkel, L. M. (1987) · Cell · doi:10.1016/0092-8674(87)90579-4 · Cited by 4,693
Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member
McPherron, A. C., Lawler, A. M., & Lee, S.-J. (1997) · Nature · doi:10.1038/387083a0 · Cited by 4,013
TEXTBOOK OF MEDICAL PHYSIOLOGY
GUYTON, A. C. (1967) · The American Journal of the Medical Sciences · doi:10.1097/00000441-196701000-00031 · Cited by 2,837
Dystrophin expression in the mdx mouse restored by stem cell transplantation
Gussoni, E., Soneoka, Y., Strickland, C. D., Buzney, E. A., Khan, M. K., Flint, A. F., Kunkel, L. M., & Mulligan, R. C. (1999) · Nature · doi:10.1038/43919 · Cited by 1,802 · cited 1×
“In comparison with conventional transgenic, cell and gene therapy approache”
BackgroundX chromosome-linked muscular dystrophy (mdx) in the mouse
Bulfield, G., Siller, W. G., Wight, P. A., & Moore, K. J. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.4.1189 · Cited by 1,765
Regulation of myostatin activity and muscle growth
Lee, S.-J., & McPherron, A. C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151270098 · Cited by 1,616 · cited 1×
“Alterations in Smad 2 and 3 phosphorylation would be predicted to regulate the formation of Smad complexes, their nuclear translocation and transcriptional regulation of genes associated with commitment of muscle progenitor”
BackgroundA deletion in the bovine myostatin gene causes the double–muscled phenotype in cattle
Grobet, L., Royo Martin, L. J., Poncelet, D., Pirottin, D., Brouwers, B., Riquet, J., Schoeberlein, A., Dunner, S., Ménissier, F., Massabanda, J., et al. (1997) · Nature Genetics · doi:10.1038/ng0997-71 · Cited by 1,556
Dystrophin protects the sarcolemma from stresses developed during muscle contraction
Petrof, B. J., Shrager, J. B., Stedman, H. H., Kelly, A. M., & Sweeney, H. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3710 · Cited by 1,526 · cited 1×
“The regimen did not completely reverse dystrophic changes; physiological parameters evaluated by ex vivo tests, such as susceptibility to damage by lengthening contraction”
BackgroundAhima, R. S., & Flier, J. S. (2000) · Annual Review of Physiology · doi:10.1146/annurev.physiol.62.1.413 · Cited by 1,428
Self-citation
Research works printed but not linked: 2
- Jalenak, M. et al. Transcriptional changes arising from in vivo inhibition of myostatin. J. Neurol. Sci. 199 (suppl)., S83 (2002)
- Engel, A. G. & Franzini-Armstrong, C. Myology (McGraw-Hill, New York, 1994)
Cited by
Items 401–500 of 853
Nakayama, Y., Nara, N., Kawakita, Y., Takeshima, Y., Arakawa, M., Katoh, M., Morita, S., Iwatsuki, K., Tanaka, K., Okamoto, S., et al. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63735-2 · Cited by 40
Current Issues in Sports and Exercise Medicine
(2013) · InTech eBooks · doi:10.5772/56649 · Cited by 38
RNA-seq reveals transcriptome changes in goats following myostatin gene knockout
Wang, L., Cai, B., Zhou, S., Zhu, H., Qu, L., Wang, X., & Chen, Y. (2017) · PLoS ONE · doi:10.1371/journal.pone.0187966 · Cited by 36
Jørgensen, L. H., Jensen, C. H., Wewer, U. M., & Schrøder, H. D. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.070435 · Cited by 35
Gamer, L. W., Nove, J., & Rosen, V. (2003) · Developmental Cell · doi:10.1016/s1534-5807(03)00027-3 · Cited by 35
Muscle and nerve pathology in Dunnigan familial partial lipodystrophy
Spuler, S., Kalbhenn, T., Zabojszcza, J., van Landeghem, F. K. H., Lüdtke, A., Wenzel, K., Koehnlein, M. R., Schuelke, M., Lüdemann, L., & Schmidt, H. (2007) · Neurology · doi:10.1212/01.wnl.0000255939.73424.f8 · Cited by 34
Gene Doping: A Review of Performance-Enhancing Genetics
Gaffney, G., & Parisotto, R. (2007) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2007.04.004 · Cited by 40
“Clearly, increasing the pain thresholddand alleviating the discomfort of nagging injuriesd would improve performance.”
BackgroundSoluble activin receptor type IIB increases forward pulling tension in the mdx mouse
Carlson, C. G., Bruemmer, K., Sesti, J., Stefanski, C. D., Curtis, H., Ucran, J. A., Lachey, J. L., & Seehra, J. S. (2011) · Muscle & Nerve · doi:10.1002/mus.21944 · Cited by 34
“The results are also consistent with the effect of long-term treatment of mdx mice with myostatin antibodies that enhanced absolute tension development but did not influence specific tension (tension normalized to cross-sectional diameter) in isolated muscle experiments.(12) Similar results were obtained by Qiao et al.”
ResultTherapeutic Strategies for Duchenne and Becker Dystrophies
Voisin, V., & de la Porte, S. (2004) · International review of cytology · doi:10.1016/s0074-7696(04)40001-1 · Cited by 36
“This lowered blood creatine kinase, reduced degeneration, increased muscle mass, and raised muscle strength as well as body weight (Bogdanovich et al., 2002).”
BackgroundTolloid cleavage activates latent GDF8 by priming the pro‐complex for dissociation
Le, V. Q., Iacob, R. E., Tian, Y., McConaughy, W., Jackson, J., Su, Y., Zhao, B., Engen, J. R., Pirruccello, M., & Springer, T. A. (2018) · The EMBO Journal · doi:10.15252/embj.201797931 · Cited by 33
Targeting TGFβ Signaling to Address Fibrosis Using Antisense Oligonucleotides
March, J. T., Golshirazi, G., Cernisova, V., Carr, H., Leong, Y., Lu‐Nguyen, N., & Popplewell, L. J. (2018) · Biomedicines · doi:10.3390/biomedicines6030074 · Cited by 37
“Furthermore, other groups confirmed fibrosis reduction in mice treated with anti-myostatin neutralizing antibodies and peptides [27,34].”
BackgroundAdvancements in stem cells treatment of skeletal muscle wasting
Meregalli, M., Farini, A., Sitzia, C., & Torrente, Y. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00048 · Cited by 36
“…the symptoms of muscular diseases, Whittemore et al. demonstrated that in wild type mice the blocking of the protein increased muscle mass (Whittemore et al., 2003) while Bogdanovich et al. showed that this condition in mdx mice improved myofibers size and muscular force (Bogdanovich et al., 2002).”
BackgroundRicaud, S., Vernus, B., Duclos, M. J. M. J., Bernardi, H., Ritvos, O., Carnac, G., & Bonnieu, A. (2003) · Oncogene · doi:10.1038/sj.onc.1207177 · Cited by 37
“The feasibility of this approach is supported by two recent reports showing that systemic administration of follistatin or injection of blocking antimyostatin antibodies can interfere with the activity of myostatin in vivo (Bogdanovich et al., 2002; Zimmers et al., 2002).”
BackgroundResultZhang, T., Yang, H., Wang, R., Xu, K., Xin, Y., Ren, G., Zhou, G., Zhang, C., Wang, L., & Zhang, Z. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.08.007 · Cited by 42
Kornegay, J. N., Bogan, D. J., Bogan, J. R., Dow, J. L., Wang, J., Fan, Z., Liu, N., Warsing, L. C., Grange, R. W., Ahn, M., et al. (2016) · Skeletal Muscle · doi:10.1186/s13395-016-0085-7 · Cited by 34
“Because mdx mice, which lack myostatin [13, 14] or in which myostatin is blocked [15] are less severely af-”
BackgroundTinklenberg, J. A., Siebers, E. M., Beatka, M. J., Meng, H., Yang, L., Zhang, Z., Ross, J. A., Ochala, J., Morris, C. A., Owens, J. M., et al. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx431 · Cited by 33
Expression of Myostatin and Follistatin inMdxMice, an Animal Model for Muscular Dystrophy
Abe, S., Soejima, M., Iwanuma, O., Saka, H., Matsunaga, S., Sakiyama, K., & Ide, Y. (2009) · ZOOLOGICAL SCIENCE · doi:10.2108/zsj.26.315 · Cited by 33
“ameliorate the pathophysiology and muscle weakness (Bogdanovich et al., 2002).”
Relation between extent of myostatin depletion and muscle growth in mature mice
Welle, S. L., Burgess, K., Thornton, C. A., & Tawil, R. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00179.2009 · Cited by 36
“The increase in muscle mass after postnatal loss of myostatin activity in mice develops because of muscle fiber hypertrophy rather than addition of new muscle fibers and does not require addition of new myonuclei (1, 4, 6, 9, 11, 20, 26, 32, 39, 42, 44).”
BackgroundWilloughby, D. S. (2004) · International Journal of Sport Nutrition and Exercise Metabolism · doi:10.1123/ijsnem.14.4.461 · Cited by 32
Targeting a therapeutic LIF transgene to muscle via the immune system ameliorates muscular dystrophy
Welc, S. S., Flores, I., Wehling‐Henricks, M., Ramos, J. N., Wang, Y., Bertoni, C., & Tidball, J. G. (2019) · Nature Communications · doi:10.1038/s41467-019-10614-1 · Cited by 33
Loro, E., Sengupta, K., Bogdanovich, S., Whig, K., Schultz, D., Huryn, D. M., & Khurana, T. S. (2020) · Scientific Reports · doi:10.1038/s41598-020-58737-6 · Cited by 33
Self-citationProtective Effect of Angiotensin 1–7 on Sarcopenia Induced by Chronic Liver Disease in Mice
Aguirre, F. S., Ábrigo, J., González, F., González, A., Simón, F., & Cabello‐Verrugio, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113891 · Cited by 32
“When the experiment finished, contractile properties were evaluated in isolated muscles by electrophysiological measurements [12,42,43].”
MethodAhmad, S. S., Ahmad, K., Lee, E. J., Shaikh, S., & Choi, I. (2021) · Molecules · doi:10.3390/molecules26175407 · Cited by 32
Proteomic analysis of secreted proteins from skeletal muscle cells during differentiation
Ojima, K., Oe, M., Nakajima, I., Shibata, M., CHIKUNI, K., Muroya, S., & Nishimura, T. (2014) · EuPA Open Proteomics · doi:10.1016/j.euprot.2014.08.001 · Cited by 34
Qi, Y., Zuo, Y., Yeh, E. T. H., & Cheng, J. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.518282 · Cited by 32
Gomes, A. R. S., Soares, A. G., Peviani, S. M., Nascimento, R. B., Moriscot, A. S., & Salvini, T. F. (2006) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/j.apmr.2005.08.126 · Cited by 37
Han, D., Huang, H., Wang, T., Hung, M., Ke, J., Chang, K., Chang, H., Ho, Y., Hsieh, W., & Yang, W. (2010) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22740 · Cited by 36
Welle, S. L. (2009) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00154.2009 · Cited by 35
Dowling, P., Lohan, J., & Ohlendieck, K. (2003) · European Journal of Cell Biology · doi:10.1078/0171-9335-00315 · Cited by 42
“, 2000) and pharmacological intervention (Badalamente and Stracher, 2000; Tidball and Spencer, 2000; Bogdanovich et al., 2002).”
Diet and exercise in frailty and sarcopenia. Molecular aspects
Millan-Domingo, F., Garcia-Dominguez, E., Gambini, J., Olaso-Gonzalez, G., Viña, J., & Gomez-Cabrera, M. C. (2024) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2024.101322 · Cited by 31
Foley, J. W., Bercury, S. D., Finn, P. F., Cheng, S. H., Scheule, R. K., & Ziegler, R. J. (2010) · Molecular Therapy · doi:10.1038/mt.2010.110 · Cited by 31
Thevis, M., Thomas, A., & Schänzer, W. (2014) · Expert Review of Proteomics · doi:10.1586/14789450.2014.965159 · Cited by 31
“, Duchenne muscular dystrophy) [1] as well as the 21st century ‘epidemic’ occurrences of diabetes mellitus [2,3] or anemia [4] are considered, tackled by (competitive) inhibitory, interfering or activating properties of the peptidic drugs as well as their function in hormone replacement therapies.”
BackgroundMyostatin deficiency is associated with lipidomic abnormalities in skeletal muscles
Baati, N., Feillet‐Coudray, C., Fouret, G., Vernus, B., Goustard, B., Coudray, C., Lecomte, J., Blanquet, V., Magnol, L., Bonnieu, A., et al. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2017.06.017 · Cited by 31
“E In addition, a decrease of fatty acid translocase (FAT/CD36) level, a lipid transporter, and the citrate synthase (CS) activity, one of the main mitochondrial oxidative enzyme, associated with a lower peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC1-α) expression has…”
Balsano, R., Kruize, Z., Lunardi, M., Comandatore, A., Barone, M., Cavazzoni, A., Cecconi, A. D. R., Morelli, L., Wilmink, H. W., Tiseo, M., et al. (2022) · Cells · doi:10.3390/cells11172671 · Cited by 31
Evaluation of serum MMP-9 as predictive biomarker for antisense therapy in Duchenne
Lourbakos, A., Yau, N., de Bruijn, P., Hiller, M., Kozaczynska, K., Jean-Baptiste, R., Reza, M., Wolterbeek, R., Koeks, Z., Ayoglu, B., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17982-y · Cited by 31
Fischetto, G., & Bermon, S. (2013) · Sports Medicine · doi:10.1007/s40279-013-0075-4 · Cited by 37
“Following these clinical and biological reports, extensive medical research has been conducted in order to produce small propeptides, or follistatin, or a mutant version of myostatin (both gene induced), which would be able to block the receptor from binding normal myostatin in muscular dystrophic patients [108].”
BackgroundFougère, B., Vellas, B. J., van Kan, G. A., & Cesari, M. (2015) · Translational Neuroscience · doi:10.1515/tnsci-2015-0009 · Cited by 33
RetractedHauerslev, S., Vissing, J., & Krag, T. O. B. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100594 · Cited by 31
“dependent repression of MyoD that is evident even in HGF/LIFtreated animals, and lead to an increase in muscle mass [2].”
BackgroundSelf-citationOhsawa, Y., Takayama, K., Nishimatsu, S., Okada, T., Fujino, M., Fukai, Y., Murakami, T., Hagiwara, H., Itoh, F., Tsuchida, K., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0133713 · Cited by 33
“These inhibitors include neutralizing antibodies against the myostatin ligand [30], its type II receptors [31], and type II decoy receptors [10,32], and a small molecule that inhibits type I receptors [13].”
BackgroundComparative Proteomic and Transcriptomic Analysis of Follistatin-Induced Skeletal Muscle Hypertrophy
Barbé, C., Bray, F., Gueugneau, M., Flament, S., Lause, P., Tokarski, C., Rolando, C. H., & Thissen, J. (2017) · Journal of Proteome Research · doi:10.1021/acs.jproteome.7b00069 · Cited by 32
Bowman-Birk inhibitor attenuates dystrophic pathology in mdx mice
Morris, C. A., Selsby, J. T., Morris, L. D., Pendrak, K., & Sweeney, H. L. (2010) · Journal of Applied Physiology · doi:10.1152/japplphysiol.01283.2009 · Cited by 32
Self-citationDrug Discovery of Therapies for Duchenne Muscular Dystrophy
Blat, Y., & Blat, S. (2015) · SLAS DISCOVERY · doi:10.1177/1087057115586535 · Cited by 34
Péladeau, C. L., Ahmed, A., Amirouche, A., Parks, T. E. C., Bronicki, L., Ljubicic, V., Renaud, J., & Jasmin, B. J. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv444 · Cited by 34
“sistance to eccentric contractions has been observed in previous pre-clinical studies with the mdx mouse (91), including ours using AICAR treatment (53).”
MethodFunctional improvement of dystrophic muscle by repression of utrophin: let-7c interaction
Mishra, M. K., Loro, E., Sengupta, K., Wilton, S. D., & Khurana, T. S. (2017) · PLoS ONE · doi:10.1371/journal.pone.0182676 · Cited by 29
Self-citationSynaptic Scaling—An Artificial Neural Network Regularization Inspired by Nature
Hofmann, M. R., & Mäder, P. (2021) · IEEE Transactions on Neural Networks and Learning Systems · doi:10.1109/tnnls.2021.3050422 · Cited by 37
“Other researchers found the existence of homeostatic plasticity to be linked with the success of natural learning processes [48]–[54].”
BackgroundMitra, A., Qaisar, R., Bose, B., & Sudheer Shenoy, P. (2023) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2023.03.008 · Cited by 30
Plasma myostatin measured by a competitive ELISA using a highly specific antiserum
Wintgens, K. F., Dschietzig, T. B., Stoeva, S., Paulsson, M., & Armbruster, F. P. (2012) · Clinica Chimica Acta · doi:10.1016/j.cca.2012.04.023 · Cited by 29
“Since then, the Myo topic has been raising enormous scientific and also agricultural interest, for obvious reasons:While inman the use of Myo-inactivating therapeutic approaches appears most promising for patients suffering from cachexia, muscle dystrophy, or trauma [3,4], and most alluring in athletes [5], the very s…”
BackgroundChang, L., Niu, F., Chen, J., Cao, X., Liu, Z., Bao, X., & Xu, Y. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116654 · Cited by 30
Dystroglycan and muscular dystrophies related to the dystrophin-glycoprotein complex.
Sciandra, F., Bozzi, M., Bianchi, M., Pavoni, E., Giardina, B., & Brancaccio, A. (2003) · PubMed · Cited by 37
Yang, C., Li, X., & Rong, J. (2014) · Chinese Medicine · doi:10.1186/1749-8546-9-23 · Cited by 29
“Several myostatin inhibitors, including myostatin propeptide, monoclonal antibodies, follistatin, and follistatin-like proteins, have been evaluated for the treatment of muscle-wasting disorders [7,13,32-34].”
BackgroundElsheikh, M., Sabagh, A. E., Mohamed, I. B., Bhongade, M., Hassan, M. M., & Jalal, P. K. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i46.6028 · Cited by 37
“There exist various therapeutic interventions that can counteract the impact of myostatin, such as monoclonal antibodies, myostatin propeptide, and follistatin[190,193-196].”
Muntoni, F., Byrne, B. J., McMillan, H. J., Ryan, M. M., Wong, B. L. Y., Dukart, J., Bansal, A., Cosson, V. F., Dreghici, R. D., Guridi, M., et al. (2024) · Neurology and Therapy · doi:10.1007/s40120-023-00570-w · Cited by 31
Candidate rejuvenating factor GDF11 and tissue fibrosis: friend or foe?
Frohlich, J., & Vinciguerra, M. (2020) · GeroScience · doi:10.1007/s11357-020-00279-w · Cited by 28
Small RNA-Mediated Epigenetic Myostatin Silencing
Roberts, T. C., Andaloussi, S. E., Morris, K. V., McClorey, G., & Wood, M. J. A. (2012) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2012.15 · Cited by 32
Gawlik, K. I., Holmberg, J., Svensson, M., Einerborg, M., Oliveira, B. M. S., Deierborg, T., & Durbeej, M. (2017) · Scientific Reports · doi:10.1038/srep44059 · Cited by 27
“In fact, a large number of the therapeutic approaches in mdx mice have been successful, ranging from genetic manipulations that aim at dystrophin restoration, through pharmacological approaches targeting secondary defects of the disease, to even protein therapy 73,76,85,86 .”
Yue, F., Song, C., Huang, D., Narayanan, N., Qiu, J., Jia, Z., Yuan, Z., Oprescu, S. N., Roseguini, B. T., Deng, M., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.09.029 · Cited by 29
Xu, R., Singhal, N., Serinagaoglu, Y., Chandrasekharan, K., Joshi, M. S., Bauer, J. A., Janssen, P. M. L., & Martin, P. T. (2015) · American Journal Of Pathology · doi:10.1016/j.ajpath.2015.06.008 · Cited by 28
Myostatin is a procachectic growth factor during postnatal myogenesis
McFarlane, C., Sharma, M., & Kambadur, R. (2008) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0b013e32830007e2 · Cited by 33
Genetic modifiers of muscular dystrophy: Implications for therapy
Heydemann, A., Doherty, K. R., & McNally, E. M. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2006.06.013 · Cited by 34
A Novel In Vitro Model for Studying Quiescence and Activation of Primary Isolated Human Myoblasts
Sellathurai, J., Cheedipudi, S. M., Dhawan, J., & Schrøder, H. D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064067 · Cited by 30
Zhang, Q., Wang, K., Zhang, Y., Meng, J., Yu, F., Chen, Y., & Zhu, D. (2010) · FEBS Journal · doi:10.1111/j.1742-4658.2009.07498.x · Cited by 29
Kong, W. H., Sung, D. K., Kim, H., Yang, J., Ieronimakis, N. M., Kim, K. S., Lee, J., Kim, D., Yun, S. H., & Hahn, S. K. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.12.007 · Cited by 29
Clinical potential of ataluren in the treatment of Duchenne muscular dystrophy
Bertoni, C., & Namgoong, J. (2016) · Degenerative Neurological and Neuromuscular Disease · doi:10.2147/dnnd.s71808 · Cited by 35
Metabolic and immunologic derangements in cardiac cachexia: where to from here?
Strassburg, S., & Anker, S. D. (2006) · Heart Failure Reviews · doi:10.1007/s10741-006-9193-5 · Cited by 28
“Finally, the myostatin gene seems to be a regulator of skeletal muscle growth, since it has been shown to markedly increase body weight and muscle mass (55).”
BackgroundTherapy Insight: cardiovascular complications associated with muscular dystrophies
McNally, E. M., & MacLeod, H. M. (2005) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio0213 · Cited by 30
“Growth factors that are currently being studied for effects on skeletal muscle regeneration include insulin-like growth factor 1, and factors that inhibit myostatin”
BackgroundFritzen, A. M., Thøgersen, F. B., Qadri, K. A. N., Krag, T. O. B., Sveen, M., Vissing, J., & Jeppesen, T. D. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072188 · Cited by 27
“In line with this, studies have shown that inhibition of myostatin-actRIIB-smad pathway leads to skeletal muscle hypertrophy in mice [55].”
ResultSelf-citationTherapeutic developments in spinal muscular atrophy
Sproule, D. M., & Kaufmann, P. (2010) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285610369026 · Cited by 26
“2002] in the mdx mouse model of DMD, as well as improves extensor digitorum longus mass and contraction force [Bogdanovich et al. 2002], further prompting attention into the potential role of this pathway in affecting the severity of pathology in DMD and other neuromuscular diseases.”
BackgroundKhanjyan, M. V., Yang, J., Kayalı, R., Caldwell, T. A., & Bertoni, C. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt184 · Cited by 26
“A dramatic increase in muscle mass has been observed in animal models (5,19,20), as well as in humans (21), lacking myostatin.”
BackgroundKim, Y. S., Bobbili, N., Lee, Y. K., Jin, H., & Dunn, M. A. (2007) · Poultry Science · doi:10.1093/ps/86.6.1196 · Cited by 37
Muscle hypertrophy induced by the Ski protein: cyto‐architecture and ultrastructure
Bruusgaard, J. C., Brack, A. S., Hughes, S. M., & Gundersen, K. (2005) · Acta Physiologica Scandinavica · doi:10.1111/j.1365-201x.2005.01462.x · Cited by 27
“When myostatin is suppressed, the result is increased 2005 Scandinavian Physiological Society 141 muscle mass (Mcpherron et al. 1997, Lee &Mcpherron 2001, Bogdanovich et al. 2002; reviewed in Kocamis & Killefer 2002, Mcpherron & Lee 2002, Whittemore et al. 2003).”
BackgroundOutside in: The matrix as a modifier of muscular dystrophy
Quattrocelli, M., Spencer, M. J., & McNally, E. M. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.12.020 · Cited by 27
“A monoclonal antibody against the mature ligand form was shown to have beneficial effects on muscle mass and strength of dystrophic mice [66].”
BackgroundSherlock, S. P., Palmer, J. P., Wagner, K. R., Abdel-Hamid, H. Z., Bertini, E., Tian, C., Mah, J. K., Kostera‐Pruszczyk, A., Muntoni, F., Guglieri, M., et al. (2022) · Journal of Neurology · doi:10.1007/s00415-022-11084-0 · Cited by 26
Gehmert, S., Wenzel, C., Loibl, M., Brockhoff, G., Huber, M., Krutsch, W., Nerlich, M. N., Gosau, M., Klein, S., Schreml, S., et al. (2014) · BioMed Research International · doi:10.1155/2014/129048 · Cited by 25
“Especially, myostatin, a new member of the TGF-β superfamily, has been reported to be a negative regulator of skeletal muscle growth [9].”
BackgroundLodberg, A., van der Eerden, B. C. J., Boers-Sijmons, B., Thomsen, J. S., Brüel, A., van Leeuwen, J. P. T. M., & Eijken, M. (2019) · The FASEB Journal · doi:10.1096/fj.201801969rr · Cited by 25
The clock regulator Bmal1 protects against muscular dystrophy
Gao, H., Xiong, X., Lin, Y., Chatterjee, S., & Ma, K. (2020) · Experimental Cell Research · doi:10.1016/j.yexcr.2020.112348 · Cited by 26
Pistilli, E. E., Bogdanovich, S., Mosqueira, M., Lachey, J. L., Seehra, J. S., & Khurana, T. S. (2009) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00138.2009 · Cited by 28
“In mdx mice, these lengthening contractions induce a force loss of 20–50% after the fifth eccentric contraction (2, 3) as a result of the loss of sarcolemmal integrity in the absence of dystrophin protein.”
BackgroundMethodSelf-citationTransgenic Overexpression of Dystroglycan Does Not Inhibit Muscular Dystrophy in mdx Mice
Hoyte, K., Jayasinha, V., Xia, B., & Martin, P. T. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63158-6 · Cited by 27
Sterrenburg, E., van der Wees, C. G. C., White, S. J., Turk, R., de Menezes, R. X., van Ommen, G. B., den Dunnen, J. T., & Hoen, P. A. C. ’. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.03.004 · Cited by 27
Upregulation of the creatine synthetic pathway in skeletal muscles of mature mdx mice
McClure, W. C., Rabon, R. E., Ogawa, H., & Tseng, B. S. (2007) · Neuromuscular Disorders · doi:10.1016/j.nmd.2007.04.008 · Cited by 25
“Diseasemodifying factors implicated in the mdx mouse have been described [19], such as extra-cellular matrix alterations [20–23], naturally occurring and experimental up-regulation of utrophin [24–27], myostatin inhibition [28,29], calcium protein-handling protein(s) [30–32] and enhanced satellite cell/regeneration fu…”
BackgroundSignaling networks governing skeletal muscle growth, atrophy, and cachexia
Joshi, A. S., da Silva, M. T., Kumar, S., & Kumar, A. (2025) · Skeletal Muscle · doi:10.1186/s13395-025-00397-z · Cited by 27
“Several studies have shown that genetic or pharmacological inhibition of myostatin leads to skeletal muscle hypertrophy [97, 98].”
Szláma, G., Trexler, M., & Patthy, L. (2013) · FEBS Journal · doi:10.1111/febs.12377 · Cited by 24
Satellite cell-specific deletion of Cipc alleviates myopathy in mdx mice
Zheng, J., Lou, J., Li, Y., Qian, P., He, W., Hao, Y., Xue, T., Li, Y., & Song, Y. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110939 · Cited by 25
Characterisation of connective tissue from the hypertrophic skeletal muscle of myostatin null mice
Elashry, M. I., Collins‐Hooper, H., Vaiyapuri, S., & Patel, K. (2012) · Journal of Anatomy · doi:10.1111/j.1469-7580.2012.01503.x · Cited by 24
“Inhibition of myostatin signalling using epigenetic approaches has already been shown to increase muscle growth in adult animals and to increase muscle mass in mouse models of DMD (Bogdanovich et al. 2002; Matsakas et al. 2009).”
BackgroundInfluentialGeng, J., Peng, F., Xiong, F., Shang, Y., Zhao, C., Li, W., & Zhang, C. (2009) · Cytotherapy · doi:10.3109/14653240903131632 · Cited by 25
Takayama, K., Rentier, C., Asari, T., Nakamura, A., Saga, Y., Shimada, T., Nirasawa, K., Sasaki, E., Muguruma, K., Taguchi, A., et al. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00168 · Cited by 23
Sarcopenia as the Mobility Phenotype of Aging: Clinical Implications
Ji, S., Jung, H., Baek, J. Y., Jang, I., & Lee, E. (2024) · Journal of Bone Metabolism · doi:10.11005/jbm.2024.31.1.1 · Cited by 27
“[77] In animal models, genetic inhibition of myostatin increases muscle function,[78] and this effect has been re-ported in humans .”
Miao, Y., Yang, J., Xu, Z., Lü, J., Zhao, S., & Li, X. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16047976 · Cited by 24
“Blocking the myostatin signaling transduction pathway can induce a highly muscled phenotype [21].”
BackgroundAssociation of the K153R polymorphism in the myostatin gene and extreme longevity
Garatachea, N., Pinós, T., Cámara, Y., Rodríguez‐Romo, G., Emanuele, E., Ricevuti, G., Venturini, L., Santos‐Lozano, A., Santiago, C., Fiuza‐Luces, C., et al. (2013) · AGE · doi:10.1007/s11357-013-9513-3 · Cited by 25
“Myostatin loss or inhibition has proven effective in ameliorating symptoms of weakness in several animal models of muscle injury, atrophy and disease (Benny Klimek et al. 2010; Bogdanovich et al. 2002; Lee and McPherron 2001; Liu et al. 2008; Morrison et al. 2009; Murphy et al. 2010; Qiao et al. 2009; Siriett et al. 2…”
InfluentialThe role of myostatin and bone morphogenetic proteins in muscular disorders
Tsuchida, K. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.2.147 · Cited by 24
“Recently, antibody-mediated myostatin blockage in mdx mice was used to improve dystrophy [19].”
BackgroundMethodInfluentialEffect of postdevelopmental myostatin depletion on myofibrillar protein metabolism
Welle, S. L., Mehta, S., & Burgess, K. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00509.2010 · Cited by 25
Novel treatments for cancer cachexia
Bossola, M., Pacelli, F., & Doglietto, G. B. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.8.1241 · Cited by 24
“Recently, an antibody against myostatin has been developed (JA16 antibody) and has been shown to be effective in blocking the myostatin activity in vivo in dystropic mice [93,94] .”
BackgroundThe Potential Role of HMGB1 Release in Peritoneal Dialysis-Related Peritonitis
Cao, S., Li, S., Li, H., Xiong, L., Zhou, Y., Fan, J., Yu, X., & Mao, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054647 · Cited by 22
“HMGB1 triggers, amplifies and extends the inflammatory response by inducing cytokine release and mediating cell injury and necrosis [16,21,22].”
BackgroundBéchir, N., Pecchi, É., Vilmen, C., Fur, Y. L., Amthor, H., Bernard, M., Bendahan, D., & Giannesini, B. (2016) · The FASEB Journal · doi:10.1096/fj.201600271rr · Cited by 23
“These data corroborate ex vivo experiments in extensor digitorum longus muscle from sActRIIB-Fc-treated mdx mice (3, 17, 18) and further evidence that muscle capacity for generating force takes full advantage of muscle hypertrophy.”
BackgroundResultExpression profiling of disease progression in canine model of Duchenne muscular dystrophy
Brinkmeyer‐Langford, C., Chu, C. P., Balog-Alvarez, C. J., Yu, X., Cai, J. J., Nabity, M. B., & Kornegay, J. N. (2018) · PLoS ONE · doi:10.1371/journal.pone.0194485 · Cited by 24
Effects of a CRF2R agonist and exercise on mdx and wildtype skeletal muscle
Hall, J. E., Kaczor, J. J., Hettinga, B. P., Isfort, R. J., & Tarnopolsky, M. A. (2007) · Muscle & Nerve · doi:10.1002/mus.20820 · Cited by 24
“The three main findings of this study are: (1) administration of a CRF2R agonist resulted in an increase in muscle weight in both mdx and wildtype mice; (2) mdx mice that were exercised or given a CRF2R agonist had lower serum CK activity; and (3) both mdx and wildtype mice treated with the CRF2R agonist had lower hea…”
BackgroundTherapy Development for Spinal Muscular Atrophy in SMN Independent Targets
Tsai, L. (2012) · Neural Plasticity · doi:10.1155/2012/456478 · Cited by 23
“Inhibition of myostatin increases muscle mass and strength in wild-type rodents and improves the pathophysiology of a mouse model for muscular dystrophy [124, 125].”
BackgroundBianchi, A., Manti, P. G., Lucini, F., & Lanzuolo, C. (2018) · Nucleus · doi:10.1080/19491034.2018.1460044 · Cited by 23
Zhou, S., Qian, B., Wang, L., Zhang, C., Hogan, M. V., & Li, H. (2018) · Muscle & Nerve · doi:10.1002/mus.26195 · Cited by 23
Guiner, C. L., Xiao, X., Larcher, T., Lafoux, A., Huchet, C., Toumaniantz, G., Adjali, O., Anegón, I., Remy, S., Grieger, J., et al. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.05.017 · Cited by 24
“30 Septem This is an open access article under the CC BY-NC-ND license (http: weakness and wasting.(4,5) All muscles are affected, including the heart and respiratory muscles.”
BackgroundMosler, S., Pankratz, C., Seyfried, A., Piechotta, M., & Diel, P. R. (2011) · Archives of Toxicology · doi:10.1007/s00204-011-0740-z · Cited by 24
Metadata
- Authors
- Bogdanovich, S., Krag, T. O. B., Barton, E. R., Morris, L. D., Whittemore, L.-A., Ahima, R. S., & Khurana, T. S.
- Affiliations
- University of Pennsylvania (US)
- Pfizer (United States) (US)
- Corresponding author
- Khurana, Tejvir S.
- Venue
- Nature
- Published
- 2002-11
- Volume
- 420
- Issue
- 6914
- Pages
- 418-421
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2083700023
- Semantic Scholar
- 590fb54cd1f2d89d44f4e1ad999be802dc756277
- Cited by
- 831
- References
- 31
- Citations by year
- 2026: 11 · 2025: 12 · 2024: 19 · 2023: 15 · 2022: 21 · 2021: 20 · 2020: 23 · 2019: 32 · 2018: 23 · 2017: 34 · 2016: 28 · 2015: 43 · 2014: 34 · 2013: 38 · 2012: 48
- FWCI
- 12.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institutes of Health
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiomyopathy and Myosin Studies
- Keywords
- myostatin, Duchenne muscular dystrophy, mdx mice, muscle atrophy, blocking antibodies, muscle mass, muscle strength, muscle degeneration, creatine kinase, TGF-beta superfamily, skeletal muscle growth
- MeSH terms
- Animals, Antibodies, Body Weight, Creatine Kinase, Male, Muscular Dystrophy, Animal, Organ Size, Transforming Growth Factor beta, Mice, Inbred mdx, Muscle, Skeletal, Muscle Fibers, Skeletal, Muscular Dystrophy, Duchenne, Mice, Myostatin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.